Enovis Corporation (NYSE:ENOV – Get Free Report) Director Angela Lalor bought 880 shares of the company’s stock in a transaction dated Friday, November 13th. The stock was purchased at an average cost of $28.27 per share, for a total transaction of $24,877.60. Following the completion of the transaction, the director owned 34,997 shares of the company’s stock, valued at $989,365.19. This represents a 2.58% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Enovis Trading Up 0.6%
Shares of ENOV stock traded up $0.17 during trading hours on Monday, reaching $27.85. 1,258,195 shares of the stock traded hands, compared to its average volume of 1,879,055. The company has a quick ratio of 1.08, a current ratio of 2.15 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $1.61 billion, a PE ratio of 8.18 and a beta of 1.31. Enovis Corporation has a 1-year low of $16.70 and a 1-year high of $31.67. The business has a fifty day moving average price of $20.71 and a 200 day moving average price of $23.25.
Enovis (NYSE:ENOV – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.11. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The firm had revenue of $558.73 million during the quarter, compared to analyst estimates of $557.12 million. During the same quarter last year, the business posted $0.75 EPS. The company’s revenue was up 1.8% on a year-over-year basis. On average, equities research analysts forecast that Enovis Corporation will post 3.15 EPS for the current year.
Analyst Ratings Changes
Several research firms recently weighed in on ENOV. Citigroup reissued a “market outperform” rating on shares of Enovis in a research report on Wednesday, September 2nd. Citizens Jmp lowered their target price on Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a research note on Wednesday, September 2nd. Needham & Company LLC upped their target price on Enovis from $34.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 2nd. Finally, UBS Group reaffirmed a “buy” rating and set a $44.00 price objective on shares of Enovis in a research report on Monday, October 5th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $38.62.
Get Our Latest Report on Enovis
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. IFP Advisors Inc increased its holdings in Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after buying an additional 1,174 shares during the last quarter. Allworth Financial LP bought a new position in Enovis during the second quarter valued at approximately $36,000. Integrated Wealth Concepts LLC acquired a new stake in Enovis in the second quarter valued at approximately $39,000. Public Employees Retirement System of Ohio acquired a new stake in Enovis in the second quarter valued at approximately $48,000. Finally, SBI Securities Co. Ltd. acquired a new stake in Enovis in the third quarter valued at approximately $55,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.
About Enovis
Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.
Featured Articles
- Five stocks we like better than Enovis
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
